Partially protective immunity induced by the 14-3-3 protein from Trichinella spiralis.
Trichinellosis, a widespread zoonosis, is considered to be an emerging or re-emerging infectious parasitic disease. The development of vaccines to prevent Trichinella infection in domestic animals and humans is important for disease control. In a previous study, we identified Ts14-3-3 as an immunodominant protein from Trichinella spiralis (T. spiralis) adult worms recognized by early infection sera from pigs and mice. In this study, we further confirmed that Ts14-3-3 mRNA is expressed in both adult worms and in the larval stages of T. spiralis. Immunostaining with anti-Ts14-3-3 mouse sera further confirmed that native Ts14-3-3 is highly expressed on the surface of T. spiralis muscle larvae. The immune recognition by infected sera, its expression in both adult and larval stages and its exposure on the surface of the parasite led us to explore Ts14-3-3 as a vaccine antigen. Recombinant Ts14-3-3 formulated with an ISA50v2 adjuvant produced strong total IgG and balanced IgG1 and IgG2a responses in vaccinated mice and stimulated mouse splenocytes to produce high levels of Th1 (INF-γ, IL-2) and Th2 (IL4, IL5) cytokines. These results indicate that Ts14-3-3 is highly immunogenic and is able to induce balanced Th1/Th2 immune responses. These vaccine-induced immune responses resulted in a reduction in muscle larvae of up to 46.2% in vaccinated mice upon subsequent larval challenge relative to the number of larvae in mice received PBS control. The significant reduction in muscle larvae in vaccinated mice suggests that Ts14-3-3 is a promising vaccine target for potential use in domestic pigs to prevent trichinellosis transmission.